Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky. Merger with Tourmaline Bio (TRML) on Oct. 19. 2023. TRML is the surviving entity. Show more

Location: | Website: talaristx.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$17.37

Open

$17.26

Volume

157,333

Day Range

$17.07 - $18.08

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

11.91%

Institutional Own.

77.67%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.